PL3906927T3 - Zastosowanie częściowych agonistów dopaminy D3 do leczenia zaburzeń ośrodkowego układu nerwowego - Google Patents
Zastosowanie częściowych agonistów dopaminy D3 do leczenia zaburzeń ośrodkowego układu nerwowegoInfo
- Publication number
- PL3906927T3 PL3906927T3 PL20305429.1T PL20305429T PL3906927T3 PL 3906927 T3 PL3906927 T3 PL 3906927T3 PL 20305429 T PL20305429 T PL 20305429T PL 3906927 T3 PL3906927 T3 PL 3906927T3
- Authority
- PL
- Poland
- Prior art keywords
- dopamine
- nervous system
- central nervous
- system disorders
- partial agonists
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 208000015114 central nervous system disease Diseases 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 239000004031 partial agonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305429.1A EP3906927B1 (en) | 2020-05-04 | 2020-05-04 | Use of dopamine d3 partial agonists for treating central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3906927T3 true PL3906927T3 (pl) | 2022-07-25 |
Family
ID=70802820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20305429.1T PL3906927T3 (pl) | 2020-05-04 | 2020-05-04 | Zastosowanie częściowych agonistów dopaminy D3 do leczenia zaburzeń ośrodkowego układu nerwowego |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12582648B2 (pl) |
| EP (2) | EP3906927B1 (pl) |
| JP (2) | JP2023523862A (pl) |
| KR (1) | KR20230005860A (pl) |
| CN (1) | CN115715195A (pl) |
| AU (1) | AU2021267681A1 (pl) |
| BR (1) | BR112022022317A2 (pl) |
| CA (1) | CA3176643A1 (pl) |
| CY (1) | CY1125228T1 (pl) |
| DK (1) | DK3906927T3 (pl) |
| ES (1) | ES2925982T3 (pl) |
| HR (1) | HRP20220739T1 (pl) |
| HU (1) | HUE059092T2 (pl) |
| IL (1) | IL297706A (pl) |
| LT (1) | LT3906927T (pl) |
| PL (1) | PL3906927T3 (pl) |
| PT (1) | PT3906927T (pl) |
| RS (1) | RS63302B1 (pl) |
| SI (1) | SI3906927T1 (pl) |
| SM (1) | SMT202200332T1 (pl) |
| UA (1) | UA130345C2 (pl) |
| WO (1) | WO2021224235A1 (pl) |
| ZA (1) | ZA202211589B (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025082974A1 (en) * | 2023-10-16 | 2025-04-24 | Bioprojet Pharma | New formulations of pitolisant and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19938823A1 (de) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| CA2396351C (en) * | 1999-12-10 | 2009-11-10 | Wyeth | New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders |
| EP1591455A1 (en) * | 2004-04-29 | 2005-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Essential tremor diagnostic and treatment |
| EP2007751B1 (en) * | 2006-04-03 | 2013-08-21 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors |
| EA200870404A1 (ru) * | 2006-04-03 | 2009-04-28 | Глэксо Груп Лимитед | Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3 |
| EP1870405A1 (en) * | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| JP2018515607A (ja) * | 2015-05-07 | 2018-06-14 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 神経変性疾患を処置する組成物および方法 |
-
2020
- 2020-05-04 RS RS20220566A patent/RS63302B1/sr unknown
- 2020-05-04 SI SI202030066T patent/SI3906927T1/sl unknown
- 2020-05-04 LT LTEP20305429.1T patent/LT3906927T/lt unknown
- 2020-05-04 PT PT203054291T patent/PT3906927T/pt unknown
- 2020-05-04 DK DK20305429.1T patent/DK3906927T3/da active
- 2020-05-04 HU HUE20305429A patent/HUE059092T2/hu unknown
- 2020-05-04 SM SM20220332T patent/SMT202200332T1/it unknown
- 2020-05-04 HR HRP20220739TT patent/HRP20220739T1/hr unknown
- 2020-05-04 EP EP20305429.1A patent/EP3906927B1/en active Active
- 2020-05-04 PL PL20305429.1T patent/PL3906927T3/pl unknown
- 2020-05-04 ES ES20305429T patent/ES2925982T3/es active Active
-
2021
- 2021-05-04 BR BR112022022317A patent/BR112022022317A2/pt unknown
- 2021-05-04 US US17/922,767 patent/US12582648B2/en active Active
- 2021-05-04 EP EP21722486.4A patent/EP4146214A1/en active Pending
- 2021-05-04 CA CA3176643A patent/CA3176643A1/en active Pending
- 2021-05-04 KR KR1020227038661A patent/KR20230005860A/ko active Pending
- 2021-05-04 AU AU2021267681A patent/AU2021267681A1/en active Pending
- 2021-05-04 WO PCT/EP2021/061689 patent/WO2021224235A1/en not_active Ceased
- 2021-05-04 JP JP2022567115A patent/JP2023523862A/ja active Pending
- 2021-05-04 UA UAA202204162A patent/UA130345C2/uk unknown
- 2021-05-04 IL IL297706A patent/IL297706A/en unknown
- 2021-05-04 CN CN202180032213.0A patent/CN115715195A/zh active Pending
-
2022
- 2022-06-09 CY CY20221100402T patent/CY1125228T1/el unknown
- 2022-10-24 ZA ZA2022/11589A patent/ZA202211589B/en unknown
-
2025
- 2025-06-18 JP JP2025102427A patent/JP2025120504A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230165852A1 (en) | 2023-06-01 |
| RS63302B1 (sr) | 2022-07-29 |
| US12582648B2 (en) | 2026-03-24 |
| JP2023523862A (ja) | 2023-06-07 |
| CY1125228T1 (el) | 2025-03-28 |
| WO2021224235A1 (en) | 2021-11-11 |
| LT3906927T (lt) | 2022-08-10 |
| BR112022022317A2 (pt) | 2022-12-13 |
| PT3906927T (pt) | 2022-07-27 |
| HRP20220739T1 (hr) | 2022-08-19 |
| HUE059092T2 (hu) | 2022-10-28 |
| EP3906927B1 (en) | 2022-05-25 |
| EP4146214A1 (en) | 2023-03-15 |
| DK3906927T3 (da) | 2022-06-20 |
| CN115715195A (zh) | 2023-02-24 |
| AU2021267681A1 (en) | 2022-12-01 |
| JP2025120504A (ja) | 2025-08-15 |
| EP3906927A1 (en) | 2021-11-10 |
| KR20230005860A (ko) | 2023-01-10 |
| ZA202211589B (en) | 2023-04-26 |
| SMT202200332T1 (it) | 2022-09-14 |
| IL297706A (en) | 2022-12-01 |
| SI3906927T1 (sl) | 2022-08-31 |
| UA130345C2 (uk) | 2026-01-28 |
| CA3176643A1 (en) | 2021-11-11 |
| ES2925982T3 (es) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4010072A4 (en) | TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | |
| SMT202500143T1 (it) | Triptamine specifiche per uso nel trattamento di disturbi dell'umore | |
| EA201992474A3 (ru) | Агонисты 5ht для лечения нарушений | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| IL276725A (en) | JAK1 pathway inhibitors for the treatment of cytokine-related disorders | |
| EP4048263A4 (en) | METHOD FOR TREATING NEURONOLOGICAL DISORDERS USING PARTIAL ALPHA 1A-AR AGONISTS | |
| UA98783C2 (en) | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | |
| IL313097A (en) | Methods of treating cns disorders | |
| GB2605422B (en) | Treatment of the central nervous system | |
| IL288655A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| IL307607A (en) | Tetracyclic compounds for the treatment of brain disorders | |
| IL283654A (en) | Decarboxylase inhibitors for the treatment of Parkinson's disease | |
| ZA202211589B (en) | Use of dopamine d3 partial agonists for treating central nervous system disorders | |
| IL289221A (en) | Compounds for the treatment of vision disorders | |
| GB201914034D0 (en) | Treatment of neurological disorders | |
| EP4114855A4 (en) | USE OF ANTI-FAM19A1 ANTAGONISTS TO TREAT CENTRAL NERVOUS SYSTEM DISEASES | |
| MX2009012716A (es) | Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. | |
| IL263494B1 (en) | Use of lithium benzoate to treat disorders of the central nervous system | |
| PL3664787T3 (pl) | Zastosowanie selektywnych agonistów receptora serotoninowego 5-HT1A do leczenia skutków ubocznych inhibitorów VMAT | |
| SG10202101500WA (en) | PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS | |
| EP3982943A4 (en) | Combination treatments for central nervous system disorders | |
| IL289012A (en) | Treatment of cns disorders with sleep disturbances | |
| ZA201700037B (en) | Compounds for the treatment of seizures and other central nervous system disorders and conditions | |
| HK40085342A (en) | Use of anti-fam19a1 antagonists for treating central nervous system diseases | |
| SG11202106517WA (en) | Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors |